Adimmune Corporation – FDA 483
Adimmune Corporation in Taichung City, Taiwan, received a Form 483 following a Pre-Approval Inspection, citing significant deficiencies across multiple areas. Observations included improper storage of drug products, failure to validate supplier analyses, inadequate preventive maintenance procedures, and numerous instances of staff not adhering to aseptic operation practices and cleaning protocols. These issues indicate a lack of adherence to established procedures and a need for improved quality system controls.
- Company
- Adimmune Corporation
- Product type
- biologics
ID · e750cffe-1872-4ea6-8fcd-5e41cca00732
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.